Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 6/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312873 | 0.94 | PGK1 (0.47) | PGK1GSK3BMAP4K2PSMB8SRC | |
| SCHEMBL10401282 | 0.87 | STING1 (0.44) | PGK1ALOX15ATM | |
| SCHEMBL21663984 | 0.83 | ALOX15 (0.43) | PGK1PSMB8SRCNPC1RAB9A | |
| SCHEMBL21688901 | 0.82 | ALOX15 (0.39) | PGK1NPC1RAB9AKMT2AALOX15 | |
| SCHEMBL12908841 | 0.80 | PSMB8 (0.45) | PGK1PSMB8NPC1RAB9AKMT2A | |
| SCHEMBL12312875 | 0.79 | ILK (0.47) | ALOX15ATM | |
| SCHEMBL935534 | 0.76 | PSMB8 (0.45) | PGK1PSMB8 | |
| SCHEMBL21091211 | 0.76 | CYP3A4 (0.53) | PGK1GSK3BMAP4K2NPC1RAB9A | |
| SCHEMBL9796864 | 0.76 | PSMB8 (0.44) | GSK3BPSMB8NPC1RAB9AKMT2A | |
| SCHEMBL935523 | 0.75 | CTSS (0.40) | ALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454329-B1 | FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2454329-B1 | FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-8772501-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772501-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8367842-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367842-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2454329-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008912-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008912-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | GUSB, CHLSN, NQO1 | PGK1 4522/4885GSK3B 3604/4885MAP4K2 4611/4885 |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | GUSB, CHLSN, NQO1 | PGK1 4522/4885GSK3B 3604/4885MAP4K2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.